SCHEMBL71770

SCHEMBL71770

O=C(CCl)OP(=O)(O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionic Acid SCHEMBL28073066 0.87 FFAR3 (0.42)
SCHEMBL71769 0.80 TSHR (0.35)
SCHEMBL28647980 0.79 CA4 (0.40)
SCHEMBL7605280 0.79
SCHEMBL285627 0.77 CA4 (0.48)
SCHEMBL10563126 0.77 CA4 (0.48)
SCHEMBL368535 0.74
SCHEMBL27473070 0.74 CA4 (0.46)
SCHEMBL9619452 0.74 CA4 (0.46)
SCHEMBL1643232 0.74 CA4 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4499 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1659178-B1 A process for the purification or production of a MAGE protein GLAXOSMITHKLINE BIOLOG SA (BE) 2010-03-31 EP claimed
CN-1026899-C Preparation method of flocculation-scale inhibitor for sugar SOUTH CHINA SCIENCE AND TECHNO (CN) 1994-12-07 CN claimed
CN-1039060-A The preparation method of flocculent dirt-separating agent for sugar refining SOUTH CHINA SCIENCE & TECHNOLO (CN) 1990-01-24 CN claimed
EP-4748862-A2 HETERODIMERIC PROTEINS Xencor, Inc. (US) 2026-05-27 EP disclosed
EP-3620473-B1 NOVEL HETERODIMERIC PROTEINS XENCOR INC (US) 2026-05-27 EP disclosed
EP-3865514-B9 BISPECIFIC ANTIBODY BINDING DLL3 AND CD3 AMGEN RES MUNICH GMBH (DE) 2026-05-20 EP disclosed
US-12630650-B2 Engineered IgA antibodies and methods of use TIGATX, INC. (US) 2026-05-19 US disclosed
US-20260132199-A1 ANTIBODY CONSTRUCTS FOR DLL3 AND CD3 AMGEN RES MUNICH GMBH (DE) 2026-05-14 US disclosed
EP-4741424-A2 FC VARIANTS WITH ALTERED BINDING TO FCRN Xencor, Inc. (US) 2026-05-13 EP disclosed
CN-122029189-A Anti-SARS-CoV-2 spike (S) antibodies and their use in treatment COVID-19 诺瓦瓦克斯股份有限公司 2026-05-12 CN disclosed
EP-3817770-B1 ANTI-STEAP1 ANTIGEN-BINDING PROTEIN AMGEN INC (US) 2026-05-06 EP disclosed
EP-0391088-A2 Use of functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy CENTER FOR BLOOD RESEARCH LABORATORIES, INC. (US) 1990-10-10 EP disclosed
WO-1990010453-A1 USE OF INTERCELLULAR ADHESION MOLECULES, AND THEIR BINDING LIGANDS IN THE TREATMENT OF ASTHMA BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1990-09-20 WO disclosed
EP-0387701-A1 Use of intercellular adhesion molecules, and their binding ligands in the treatment of asthma Boehringer Ingelheim Pharmaceuticals Inc. (US) 1990-09-19 EP disclosed
EP-0387668-A1 Intercellular adhesion molecule - 2 and its binding ligands CENTER FOR BLOOD RESEARCH LABORATORIES, INC. (US) 1990-09-19 EP disclosed
WO-1990007572-A1 HUMAN DNase GENENTECH, INC. (US) 1990-07-12 WO disclosed
EP-0362272-A1 METHOD AND COMPOSITIONS FOR MAKING ACSF AND ACSF ANTAGONISTS. GENENTECH INC (US) 1990-04-11 EP disclosed
CN-1039060-A The preparation method of flocculent dirt-separating agent for sugar refining SOUTH CHINA SCIENCE & TECHNOLO (CN) 1990-01-24 CN disclosed
WO-1989012678-A1 PURIFIED UBIQUITIN HYDROLASE, DNA SEQUENCES ENCODING SAME, AND ITS USE IN RECOVERING POLYPEPTIDES GENENTECH, INC. (US) 1989-12-28 WO disclosed
WO-1988009376-A1 METHOD AND COMPOSITIONS FOR MAKING ACSF AND ACSF ANTAGONISTS GENENTECH, INC. (US) 1988-12-01 WO disclosed